Celea Therapeutics
Latest round
- Seed
Last raised
- Jul 2026
Total raised
- $180M
Investors
- 3
About Celea Therapeutics
Based in the US, Celea Therapeutics, Inc. is a biotechnology company specializing in innovative therapies for serious respiratory diseases, particularly idiopathic pulmonary fibrosis, through the development of advanced pharmaceutical solutions. Celea Therapeutics, Inc. focuses on developing therapies for individuals with serious respiratory diseases, having been founded with a vision to address unmet medical needs and Sven Dethlefs is the Chief Executive Officer. The company is headquartered in Boston, US.00 mn. Celea Therapeutics is focused on developing innovative therapies for individuals suffering from serious respiratory diseases, with a particular emphasis on idiopathic pulmonary fibrosis (IPF). The company’s lead product, deupirfenidone, is an oral antifibrotic medication currently in Phase 3 clinical trials. Designed to be a next-generation treatment, deupirfenidone builds upon the established efficacy and safety profile of the FDA-approved drug pirfenidone, offering a modified approach that aims to reduce lung function decline. The company integrates the lived experiences of patients into its product development, ensuring that the therapies address significant unmet medical needs. Celea Therapeutics serves a global market, particularly targeting regions that include North America and Europe, where the burden of respiratory diseases is notably high. Celea Therapeutics generates revenue through the development and eventual commercialization of its pharmaceutical products, particularly through the anticipated launch of deupirfenidone for IPF treatment. Revenue is structured around strategic partnerships with healthcare providers and potential collaborations with pharmaceutical distributors upon market entry. The business model is primarily B2B, focusing on agreements with hospitals, specialty pharmacies, and healthcare professionals who administer the medication to patients. Given the innovative nature of its product, Celea Therapeutics may explore pricing strategies that reflect the value of their proprietary treatments, particularly considering the urgent needs of patients with progressive fibrotic lung diseases. Detailed pricing structures for deupirfenidone and other potential offerings are tailored to align with market standards and reimbursement frameworks in various healthcare systems. In July 2026, Celea Therapeutics, Inc.
Who invested in Celea Therapeutics
3 investors across 1 round
See all investors in Celea Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 2, 2026
Amount
$180M
Investors
Questions about Celea Therapeutics
Who invested in Celea Therapeutics?
Celea Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Celea Therapeutics raised?
Celea Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Celea Therapeutics last raise money?
Celea Therapeutics's most recent round on record is a Seed, in Jul 2026.
What does Celea Therapeutics do?
Based in the US, Celea Therapeutics, Inc.
Where is Celea Therapeutics headquartered?
Celea Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Celea Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Celea Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Celea Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.